Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (AlloTreo)

This is an interventional treatment trial for Leukemia Read More

Inclusion Criteria:

1. Patients with haematological malignancies, according to WHO classification, such as:

   • acute myeloid leukaemia -AML- in CR1 except "low-risk cases" defined by t(15;17), t(8;21), inv 16 or normal cytogenetics at diagnosis with FLT3-ITD negative and NPM-1 positive, with no high risk clinical criteria
   • any AML beyond CR1
   • acute lymphoblast leukaemia -ALL- in CR1 only if at "high risk" defined by cytogenetics as t(9;22), t(4;11) or for persistence of minimal residual disease (MRD)
   • any ALL beyond CR1
   • chronic myeloid leukaemia -CML- in chronic phase (CP) or accelerated phase (AP) intolerant/not responsive to TK-inhibitors
   • myeloproliferative disorders -MPD-
   • myelodysplastic syndrome -MDS- with intermediate or high risk International Prognostic Scoring System (IPSS)
   • diffuse large cell lymphoma -DLCL- with a chemosensitive relapse or beyond CR1
   • lymphoblastic and Burkitt lymphoma with a chemosensitive relapse or beyond CR1
   • mantle cell lymphoma -MCL- with a chemosensitive relapse or beyond CR1
   • follicular lymphoma -FCL- with a chemosensitive relapse or beyond CR2
   • Hodgkin lymphoma -HD- with a chemosensitive relapse or beyond CR1
   • chronic lymphocytic leukaemia -CLL- at "poor risk" in CR1 or with a chemosensitive relapse
   • CLL relapsing after high dose chemotherapy
   • T-cell non Hodgkin lymphoma -T-NHL- in CR1 or beyond
   • multiple myeloma -MM- at high risk for cytogenetics or ISS stage 3 in CR1 following high dose chemotherapy
   • MM at any relapse/progression except refractory disease

2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD)

   • HLA-identity defined by the following markers: A, B, DRB1, DQB1 or a single or double Cord Blood unit (CB) with at least a 4 out of 6 HLA-matching by the following markers: A, B and DRB.

   A) identity between the 2 CB units and the recipient;

   B) Two identical CB units with one or two mismatches with the recipient;

   C) Two CB units with one mismatch between them and two mismatches with the recipient. We will prefer mismatches either for class I or for class II antigens; we will avoid mismatches concerning both classes I and II together.

3. Target graft size (unmanipulated, preferably not cryopreserved)

   • bone marrow: 2 to 10 x 106 CD34+ cells/kg BW recipient or > 2 x 108 nucleated cells/kg BW recipient or
   • peripheral blood: 4 to 10 x 106 CD34+ cells/kg BW recipient
4. Age > 18 and < 70 years
5. Karnofsky Index > 80 %
6. Adequate contraception in female patients of child-bearing potential
7. Written informed consent

Exclusion Criteria:

1. Secondary malignancies
2. Previous allogeneic transplantation
3. Hematopoietic cell transplantation-specific comorbidity index > 4 (HCT-CI Sorror et al, Appendix M)
4. Known and manifested malignant involvement of the CNS
5. Active infectious disease
6. HIV- positivity or active hepatitis infection
7. Impaired liver function (Bilirubin > upper normal limit; Transaminases > 3.0 x upper normal limit)
8. Impaired renal function (Creatinine-clearance < 60 ml/min; Serum Creatinine > 1.5 x upper normal limit).
9. Pleural effusion or ascites > 1.0 L
10. Pregnancy or lactation
11. Known hypersensitivity to treosulfan and/or fludarabine
12. Participation in another experimental drug trial within 4 weeks before day -6
13. Non-co-operative behaviour or non-compliance
14. Psychiatric diseases or conditions that might impair the ability to give informed consent